Cancer
Immunol Immunother 2000, 49:476–484.PubMedCrossRef 26. Tang Yu, Cui XM, Yuan M, Lu SB: Primary experimental observation on mice sarcoma with heat shock protein/peptides complex for immunotherapy. Chin J Cancer Prev Treat 2006,13(9):648–650. 27. Cui XM, Yuan M, Tang Y, Lu SB: Fludarabine Therapeutic effects of mixed heat shock protein/peptides on mice sarcoma. ZhongHua ShiYan WaiKe ZaZhi 2006,23(5):636. 28. Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchianò A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Di Florio A, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G: A phase II trial of vaccination with autologous, tumor-derived heat-shock LY3039478 price protein peptide complexes gp96, in combination with GM-CSF and interferon-alpha
in metastatic melanoma patients. Cancer Immunol Immunother 2006, 55:958–968.PubMedCrossRef 29. Tsung KL, Dolan JP, Tsung LY, et al.: Macrophages as effective cells in interleukine 12 induced T cell-dependent tumor rejection. Cancer Res 2002, 62:5069–5075.PubMed 30. Colombo MP, Thiazovivin Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine & Growth Factor Reviews 2002,13(2):155–168.CrossRef 31. Gao J-Q, Sugita T, Kanagawa N, Iida K, Eto Y, Motomura Y, Mizuguchi H, Tsutsumi Y, Hayakawa T, Mayumi T, Nakagawa S: A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice Reverse transcriptase with Meth-A fibrosarcoma. Biochemical and Biophysical Research Communications 2005,328(4):1043–1050.PubMedCrossRef 32. Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park Jong-W, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH: IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001,108(1):51–62.PubMed 33. Hop N Le, Natalie C Lee,
Kangla Tsung, Jeffrey A Norton: Pre-Existing Tumor-Sensitized T Cells are essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12. Journal of Immunology 2001, 167:6765–6772. 34. Nagaraj S, Gabrilovich DI: Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008, 68:2561–2563.PubMedCrossRef 35. Sica A, Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007, 117:1155–1166.PubMedCrossRef 36. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F: Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin’s lymphoma and Hodgkin’s disease. Clin Cancer Res 2004,10(16):5432–8.PubMedCrossRef 37.